Head-to-head · Cost-Efficiency Index
Pallas Health vs Maves
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
Pallas Health
Shoppers comfortable paying a quarter at a time who want the whole cost stated before signup, and who are not looking for a month-to-month exit.
Visit Pallas HealthMaves
Shoppers drawn to aggressive low intro pricing on semaglutide who will confirm the exact charge before checkout.
Visit MavesThe verdict
Maves takes it, leading the Cost-Efficiency Index 76 to 74. Maves (operated by parent company Homera Health) is a men's-health/performance-framed telehealth platform offering compounded semaglutide and tirzepatide plus sermorelin. Pallas Health still earns a C — Shoppers comfortable paying a quarter at a time who want the whole cost stated before signup, and who are not looking for a month-to-month exit.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs Maves.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | Pallas Health | Maves |
|---|---|---|
| Cost-Efficiency Index | 74/100 | 76/100 |
| Semaglutide / mo | $199/mo average — Pallas's own figure for $597 billed every 12 weeks, its only cadence; $139 covers the first 4 weeks | $89/mo (starting dose, compounded) |
| Tirzepatide / mo | $299/mo average — Pallas's own figure for $897 billed every 12 weeks, its only cadence; $179 covers the first 4 weeks | Not disclosed |
| Semaglutide / yr (modeled) | $2,388 | $1,068 |
| Tirzepatide / yr (modeled) | $3,588 | — |
| Coverage | Most states | All 50 states |
| Oral / sublingual | No | No |
| Brand-name access | Compounded only | Yes |
| Rank here | #47 | #49 |
Pallas Health
74/100Where the value is
- Both molecules are priced publicly, with the charged block stated rather than only a monthly average
- A genuinely reduced first cycle — $139 semaglutide and $179 tirzepatide for the first four weeks
- Runs a Spanish-language lander as well as the English site, which most of this field does not
The tradeoffs
- There is no monthly rung. The only cadence is a 12-week block paid up front — $597 or $897 — so the advertised 'per month' figure is arithmetic rather than a payment anyone makes
- A 12-week cycle is 4.33 charges a year, not 4, so a year costs more than four times the block
Maves
76/100Where the value is
- LegitScript badge displayed on the site
- Publishes the FDA compounded-medication disclaimer
- Low advertised semaglutide entry price ($89-99/mo range)
The tradeoffs
- The homepage shows two different numbers for the same starting semaglutide tier ($89/month vs $99 first month) with no reconciliation — the real ongoing price cannot be confirmed from the public site
- Tirzepatide is listed as an offering but no price is published anywhere reachable on the site, confirmed by direct search
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.